We have observed
1 EP application
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after February 24, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
glycosylated protein of an extra-cellular matrix for use in a method of treating an ischemic heart of a human or animal subject in need thereof